NASDAQ: KERNAkerna Corp Stock
$0.19+0.01 (+5.56%)
Updated Sep 26, 2023
KERN Price
$0.19
Fair Value Price
$0.35
Market Cap
$1.44M
52 Week Low
$0.17
52 Week High
$2.80
P/E
-0.03x
P/B
-0.18x
P/S
0.66x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.50M
Earnings
-$33.10M
Gross Margin
38.4%
Operating Margin
-586.11%
Profit Margin
-619.2%
Debt to Equity
-1.79
Operating Cash Flow
-$8M
Beta
1.37
Next Earnings
Nov 13, 2023
Ex-Dividend
N/A
Next Dividend
N/A
KERN Overview
Akerna Corp. provides enterprise software solutions that enable regulatory compliance and inventory management in United States and Canada. The company offers MJ Platform for the cannabis, hemp, and CBD industry; and Leaf Data Systems, a government regulatory software. It also provides consulting services to cannabis industry; business intelligence, data analytics and other software related services; and Last Call Analytics, a tool for alcohol brands to analyze their retail sales analytics. In addition, the company operates seed-to-sale platform that offers tracking, reporting, and compliance tools to cannabis cultivators, processors, sellers, and clinics. Further, it provides cannabis cultivation management and compliance software; and cannabis tracking technology that offers seed-to-sale-to-self data. Akerna Corp. was founded in 2010 and is headquartered in Denver, Colorado.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how KERN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KERN ($0.19) is undervalued by 47.09% relative to our estimate of its Fair Value price of $0.35 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
KERN ($0.19) is significantly undervalued by 47.09% relative to our estimate of its Fair Value price of $0.35 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
KERN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KERN due diligence checks available for Premium users.
Be the first to know about important KERN news, forecast changes, insider trades & much more!
KERN News
Valuation
KERN fair value
Fair Value of KERN stock based on Discounted Cash Flow (DCF)
Price
$0.19
Fair Value
$0.35
Undervalued by
45.66%
KERN ($0.19) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KERN ($0.19) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KERN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KERN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.03x
Industry
55.14x
Market
14.06x
KERN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.18x
Industry
3.07x
KERN's financial health
Profit margin
Revenue
$2.3M
Net Income
-$3.1M
Profit Margin
-134.7%
KERN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
KERN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$6.4M
Liabilities
$14.6M
Debt to equity
-1.79
KERN's short-term liabilities ($12.08M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KERN's long-term liabilities ($2.49M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KERN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
KERN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.6M
Investing
$0.0
Financing
$1.5M
KERN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KERN vs Health Information Service Stocks
Akerna Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.